Literature DB >> 33799006

Expression of CD40L on CD4+T cells distinguishes active versus inactive HIV-associated Kaposi's Sarcoma.

Owen Ngalamika1, Musonda Kawimbe2, Marie Claire Mukasine2.   

Abstract

Kaposi's sarcoma (KS) is a malignancy of vascular origin. It is caused by the Kaposi's sarcoma-associated herpes virus (KSHV). Immune dysregulation is a key feature in the development and progression of KS. The main aim of this study was to determine and compare circulating CD4+ and CD8+T cell subsets including their expression of CD40 ligand (CD40L) and programmed cell death protein 1 (PD1), natural killer (NK) cells, and NK T cells between individuals with active HIV-associated KS versus those in remission. We found that the proportion of CD4+T cells was significantly higher in individuals in remission compared to those with active KS (26.3% vs 13.9%; p = 0.01). We also observed that the proportion of CD4+T cells and central memory CD4+T cells expressing CD40L was significantly higher in individuals with active KS versus those in remission, (10.6% vs 5.4%; p = 0.03) and (14.8% vs 5.9%; p = 0.01) respectively. There was no significant difference in proportion of CD4+ and CD8+ naïve, central memory, effector memory, and terminal effector cells between the two groups. In addition, there was no difference in expression of PD1 on the T cell subsets between the two groups. Furthermore, the proportion of NK cells and NK T cells were not differential between individuals with active disease versus those in remission. CD40L expression is higher in individuals with active HIV-associated KS compared to those in remission. The proportion of CD4+T cells is higher in individuals in remission compared to those with active HIV-associated KS.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CD40L; HIV; Kaposi's sarcoma; Natural killer cells; PD1; T cell subsets

Mesh:

Substances:

Year:  2021        PMID: 33799006      PMCID: PMC8127409          DOI: 10.1016/j.ctarc.2021.100361

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  19 in total

Review 1.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  Kaposi sarcoma incidence in females is nearly four-fold higher in the Lower Rio Grande Valley compared to the Texas average.

Authors:  Wendy Innis-Whitehouse; Xiaohui Wang; Nicolas Restrepo; Carlos Salas; Katia Moreno; Alvaro Restrepo; Megan Keniry
Journal:  Cancer Treat Res Commun       Date:  2018-06-19

3.  Cancer spectrum in HIV-infected patients: A zonal hospital experience in Tanzania.

Authors:  Alex Mremi; Jackline Mswima; Mathew G Mlay; Henry Bartholomew; Julius P Alloyce; Blandina T Mmbaga; John Bartlett
Journal:  Cancer Treat Res Commun       Date:  2020-09-29

4.  Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth.

Authors:  Amanda J Baxendale; Chris W Dawson; Suzanne E Stewart; Vivek Mudaliar; Gary Reynolds; John Gordon; Paul G Murray; Lawrence S Young; Aristides G Eliopoulos
Journal:  Oncogene       Date:  2005-11-24       Impact factor: 9.867

5.  The expression of CD154 by Kaposi's sarcoma cells mediates the anti-apoptotic and migratory effects of HIV-1-TAT protein.

Authors:  V Cantaluppi; M C Deregibus; L Biancone; I Deambrosis; B Bussolati; A Albini; G Camussi
Journal:  Int J Immunopathol Pharmacol       Date:  2006 Jan-Mar       Impact factor: 3.219

6.  Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.

Authors:  Giovanna Rappocciolo; Heather R Hensler; Mariel Jais; Todd A Reinhart; Amarendra Pegu; Frank J Jenkins; Charles R Rinaldo
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

Review 7.  T lymphocyte subsets in cancer immunity: Friends or foes.

Authors:  Dounia Chraa; Asmaa Naim; Daniel Olive; Abdallah Badou
Journal:  J Leukoc Biol       Date:  2018-11-02       Impact factor: 4.962

8.  Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review.

Authors:  Elaine Chang; Srikar R Mapakshi; Pamela Mbang; Nader Kim El-Mallawany; Jennifer R Kramer; Donna L White; Elizabeth Y Chiao
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.771

9.  Predicting AIDS-related events using CD4 percentage or CD4 absolute counts.

Authors:  Yasmin Pirzada; Sadik Khuder; Haig Donabedian
Journal:  AIDS Res Ther       Date:  2006-08-17       Impact factor: 2.250

10.  Iatrogenic Kaposi's sarcoma caused by corticosteroids.

Authors:  Rosana Lazzarini; Andressa Sato de Aquino Lopes; Rute Facchini Lellis; Fabiana Brasil
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

View more
  1 in total

1.  SARS-CoV-2-Specific T Cell Immunity in HIV-Associated Kaposi Sarcoma Patients in Zambia.

Authors:  Owen Ngalamika; Marie Claire Mukasine; Patrick Kamanzi; Musonda Kawimbe; Aaron Mujajati; For Yue Tso; Salum J Lidenge; Chibamba Mumba
Journal:  J Immunol Res       Date:  2022-07-28       Impact factor: 4.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.